Association between levels of hormones implied in steroid biosynthesis pathway and activity of abiraterone acetate (AA) in patients (pts) with metastatic castration- resistant prostate cancer (mCRPC): an exploratory analysis

Steroid Biosynthesis ◽

Association between levels of hormones implied in steroid biosynthesis pathway and activity of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): An exploratory analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e16066 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e16066-e16066

Author(s):

Marcello Tucci ◽

Francesca Vignani ◽

Valentina Bertaglia ◽

Consuelo Buttigliero ◽

Alfredo Berruti ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Exploratory Analysis ◽

Biosynthesis Pathway ◽

Steroid Biosynthesis ◽

Abstract CT313: An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx)

10.1158/1538-7445.am2014-ct313 ◽

2014 ◽

Cited By ~ 1

Author(s):

Eleni Efstathiou ◽

Hari Deshpande ◽

Daniel George ◽

Anthony M. Joshua ◽

Mary-Ellen Taplin ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Exploratory Analysis ◽

Efficacy And Safety ◽

Prior Chemotherapy ◽

Castration Resistant ◽

Black Patients

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer

Prostate Cancer and Prostatic Diseases ◽

10.1038/pcan.2013.41 ◽

2013 ◽

Vol 17 (1) ◽

pp. 34-39 ◽

Cited By ~ 56

Author(s):

O B Goodman ◽

T W Flaig ◽

A Molina ◽

P F A Mulders ◽

K Fizazi ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Exploratory Analysis ◽

Phase Iii ◽

Castration Resistant ◽

Phase Iii Study ◽

Visceral Disease

682 EXPLORATORY ANALYSIS OF THE SAFETY PROFILE OF ABIRATERONE ACETATE (AA) IN PATIENTS (PTS) RECEIVING CONCOMITANT RADIATION THERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

The Journal of Urology ◽

10.1016/j.juro.2012.02.764 ◽

2012 ◽

Vol 187 (4S) ◽

Cited By ~ 2

Author(s):

Fred Saad ◽

Arturo Molina ◽

Justin Li ◽

Thian Kheoh ◽

Howard I. Scher

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

Safety Profile ◽

Abiraterone Acetate ◽

Exploratory Analysis ◽

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial

The Lancet Oncology ◽

10.1016/s1470-2045(12)70473-4 ◽

2012 ◽

Vol 13 (12) ◽

pp. 1210-1217 ◽

Cited By ~ 194

Author(s):

Christopher J Logothetis ◽

Ethan Basch ◽

Arturo Molina ◽

Karim Fizazi ◽

Scott A North ◽

...

Keyword(s):

Prostate Cancer ◽

Pain Control ◽

Randomised Trial ◽

Abiraterone Acetate ◽

Exploratory Analysis ◽

Castration Resistant ◽

Skeletal Related Events

Re: Effect of Abiraterone Acetate and Prednisone Compared with Placebo and Prednisone on Pain Control and Skeletal-Related Events in Patients with Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of Data from the COU-AA-301 Randomised Trial

The Journal of Urology ◽

10.1016/j.juro.2013.01.076 ◽

2013 ◽

Vol 189 (5) ◽

pp. 1715-1715 ◽

Cited By ~ 1

Author(s):

Samir S. Taneja

Keyword(s):

Prostate Cancer ◽

Pain Control ◽

Randomised Trial ◽

Abiraterone Acetate ◽

Exploratory Analysis ◽

Castration Resistant ◽

Skeletal Related Events

105 Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC)

European Urology Supplements ◽

10.1016/s1569-9056(13)60597-7 ◽

2013 ◽

Vol 12 (1) ◽

pp. e105-e106

Author(s):

H. Suttmann ◽

P.F.A. Mulders ◽

A. Molina ◽

O.B. Goodman ◽

T.W. Flaig ◽

...

Keyword(s):

Prostate Cancer ◽

Disease Patient ◽

Abiraterone Acetate ◽

Exploratory Analysis ◽

Phase Iii ◽

Castration Resistant ◽

Phase Iii Study ◽

Visceral Disease

Re: Effect of Abiraterone Acetate and Prednisone Compared with Placebo and Prednisone on Pain Control and Skeletal-related Events in Patients with Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis of Data from the COU-AA-301 Randomised Trial

European Urology ◽

10.1016/j.eururo.2013.03.022 ◽

2013 ◽

Vol 63 (6) ◽

pp. 1132-1133

Author(s):

Evanguelos Xylinas ◽

Luis Kluth ◽

Shahrokh F. Shariat

Keyword(s):

Prostate Cancer ◽

Pain Control ◽

Randomised Trial ◽

Abiraterone Acetate ◽

Exploratory Analysis ◽

Castration Resistant ◽

Skeletal Related Events

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate

Case Medical Research ◽

10.31525/ct1-nct04158245 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Faculty Opinions recommendation of Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1118816.793494158 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Phase I ◽

Abiraterone Acetate ◽

Selective Inhibitor ◽

Phase I Clinical Trial ◽